Tiglutik, Liquid Form of Riluzole, Now Available in US for ALS Treatment

Tiglutik, an oral suspension of riluzole, is now available as a treatment for amyotrophic lateral sclerosis (ALS) in the U.S., ITF Pharma, the therapy’s developer and a subsidiary of Italfarmaco, recently announced. Rilutek (riluzole, marketed by Sanofi), has been available in the U.S. as 50 mg tablets…

Life with ALS often feels like a crash course in adaptability but being adaptable doesn’t come naturally for many of us. However, whether you’re the patient, caregiver, or a family member, I believe you can learn how. Read on and let’s get started. In my pre-ALS life…

One of the most awful parts of my diagnosis was the loss of my career. Teaching was more than a job to me — it was part of my identity. I wish I knew then that my loss wouldn’t be as total as I had imagined. Don’t give…

Chip technology — much like an organ-on-a-chip that can simulate the workings of tissue or organs  — was used to recreate amyotrophic lateral sclerosis (ALS), allowing researchers to identify two treatments for blood cancers — rapamycin plus bosutinib — as a possible ALS combination therapy. The study, “Microphysiological 3D model…

Researchers have discovered that mast cells and neutrophils — two types of immune cells — are involved in the degeneration of peripheral motor nerve cells and progression of amyotrophic lateral sclerosis (ALS). These findings also clarify why masitinib — an investigational therapy for ALS that targets mast cells…

If you are living with ALS, here’s a question for you: When was the last time you spent the time to learn something? It can’t include watching a TV newscast or scanning the news feed on your mobile device. I mean quality time spent with books or…

Half a year has gone by since disgraced pharma executive Martin Shkreli was sentenced to seven years in federal prison for securities and wire fraud while heading San Diego-based Retrophin. As founder and CEO of another company (then known as Turing Pharmaceuticals), in late 2015 Shkreli bought the rights…